E. Van Valckenborgh PhD, M. Bakkus PhD, E. Boone PhD, A. Camboni MD, PhD, J-P. Defour PhD, B. Denys MD, H. Devos MD, L. Dewispelaere MD, G. Froyen PhD, A. Hébrant PhD, P. Heimann MD, PhD, P. Hermans MD, PhD, E. Heylen PhD, K. Jacobs PhD, F. Lambert MD, M. Le Mercier Apr, PhD, E. Lierman PhD, H. Louagie MD, PhD, B. Maes MD, PhD, M-B. Maes PhD, G. Martens MD, PhD, L. Michaux MD, PhD, F. Nollet PhD, MSc, H.A. Poirel MD, PhD, G. Raicevic PhD, P. Saussoy MD, PhD, T. Tousseyn MD, PhD, M. Van Den Bulcke PhD, P. Vandenberghe MD, PhD, K. Vandepoele PhD, P. Vannuffel PhD, T. Venken PhD, K. Vermeulen PhD
Molecular diagnostics have an increasing impact on diagnosis, risk stratification and targeted treatment in haemato-oncology. In the framework of a pilot study for the implementation of next-generation sequencing in the Belgian healthcare system, the Commission of Personalised Medicine was founded to give professional and evidence-based advice on the molecular analysis in haemato-oncology. This paper describes its recommendations for NGS analysis in myeloid malignancies. In addition, the minimally required set of genes that must be analysed is defined and algorithms for molecular workflow in myeloid malignancies are proposed.
K. De Keersmaecker PhD, Z.K. Atak , N. Li , C. Vicente , S. Patchett , T. Girardi , V. Gianfelici , E. Geerdens , M. Porcu , I. Lahortiga , R. Luca , J. Yan , G. Hulselmans , E. Clappier , R. Vandepoel , B. Sweron , K. Jacobs PhD, N. Mentens , I. Wlodarska , B. Cauwelier MD, PhD, J. Cloos , J. Soulier , A. Uyttebroeck MD, PhD, C. Bagni , B. Hassan , P. Vandenberghe MD, PhD, A. Johnson , S. Aerts , J. Cools
A. Dagklis , D. Pauwels , I. Lahortiga , Z.K. Atak , K. De Keersmaecker PhD, K. Jacobs PhD, N. Mentens , A. Uyttebroeck MD, PhD, J. Maertens MD, PhD, G. Verhoef MD, PhD, S. Aerts , P. Vandenberghe MD, PhD, J. Cools